

# Lennox-Gastaut Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

<https://marketpublishers.com/r/LCDA42516D72EN.html>

Date: May 2024

Pages: 128

Price: US\$ 6,499.00 (Single User License)

ID: LCDA42516D72EN

## Abstracts

The 7 major Lennox-Gastaut syndrome markets are expected to exhibit a CAGR of 4.63% during 2024-2034.

The Lennox-Gastaut syndrome market has been comprehensively analyzed in IMARC's new report titled "Lennox-Gastaut Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Lennox-Gastaut syndrome (LGS) refers to a rare and severe form of epilepsy that primarily affects children between the ages of 3 and 5. It is characterized by multiple types of seizures, cognitive impairment, and distinct electroencephalogram (EEG) patterns. Children suffering from the ailment often experience a variety of seizure types, including tonic, atonic, and absence seizures, which can lead to sudden falls (drop attacks) and frequent episodes of loss of awareness. The cognitive and developmental challenges associated with LGS can range from mild to severe, affecting learning, behavior, and overall quality of life. The diagnosis of the illness involves a comprehensive evaluation of medical history, clinical symptoms, and EEG findings. The hallmark EEG pattern of this ailment typically includes slow spike-and-wave complexes and multifocal epileptic discharges. As various seizure types and cognitive issues overlap with numerous other epilepsy syndromes, accurately diagnosing LGS can be complex and requires expertise from neurologists and epileptologists.

The increasing incidences of brain abnormalities that can disrupt normal brain function and contribute to the development of seizures are primarily driving the Lennox-Gastaut syndrome market. In addition to this, the inflating utilization of efficacious pharmaceutical interventions like antiepileptic drugs, benzodiazepines, and cannabinoid-based medications to manage seizures and ameliorate symptomatology is also creating

a positive outlook for the market. Moreover, the widespread adoption of specialized medical devices, such as vagus nerve stimulators, which are designed to modulate brain activity and reduce seizure frequency in individuals suffering from the ailment, is further bolstering the market growth. Apart from this, the rising usage of comprehensive therapeutic approaches encompassing ketogenic diets and non-pharmacological interventions owing to their numerous advantages, including optimizing treatment outcomes, fostering cognitive development, and enhancing overall quality of life, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of progressive neuromodulation techniques like responsive neurostimulation, calibrated to detect and counteract seizure activity in patients, is also augmenting the market growth. Furthermore, the escalating application of advanced precision medicine avenues, including targeted genetic therapies tailored to rectify or replace malfunctioning genes associated with the disorder, is expected to drive the Lennox-Gastaut syndrome market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the Lennox-Gastaut syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Lennox-Gastaut syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Lennox-Gastaut syndrome market in any manner.

### Time Period of the Study

Base Year: 2023

Historical Period: 2018-2023

Market Forecast: 2024-2034

### Countries Covered

United States

Germany

France  
United Kingdom  
Italy  
Spain  
Japan

### Analysis Covered Across Each Country

Historical, current, and future epidemiology scenario  
Historical, current, and future performance of the Lennox-Gastaut syndrome market  
Historical, current, and future performance of various therapeutic categories in the market  
Sales of various drugs across the Lennox-Gastaut syndrome market  
Reimbursement scenario in the market  
In-market and pipeline drugs  
Competitive Landscape:  
This report also provides a detailed analysis of the current Lennox-Gastaut syndrome marketed drugs and late-stage pipeline drugs.

### In-Market Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

### Late-Stage Pipeline Drugs

Drug Overview  
Mechanism of Action  
Regulatory Status  
Clinical Trial Results  
Drug Uptake and Market Performance

\*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

### Key Questions Answered in this Report:

*Lennox-Gastaut Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast...*

## Market Insights

How has the Lennox-Gastaut syndrome market performed so far and how will it perform in the coming years?

What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?

What was the country-wise size of the Lennox-Gastaut syndrome market across the seven major markets in 2023 and what will it look like in 2034?

What is the growth rate of the Lennox-Gastaut syndrome market across the seven major markets and what will be the expected growth over the next ten years?

What are the key unmet needs in the market?

## Epidemiology Insights

What is the number of prevalent cases (2018-2034) of Lennox-Gastaut syndrome across the seven major markets?

What is the number of prevalent cases (2018-2034) of Lennox-Gastaut syndrome by age across the seven major markets?

What is the number of prevalent cases (2018-2034) of Lennox-Gastaut syndrome by gender across the seven major markets?

How many patients are diagnosed (2018-2034) with Lennox-Gastaut syndrome across the seven major markets?

What is the size of the Lennox-Gastaut syndrome patient pool (2018-2023) across the seven major markets?

What would be the forecasted patient pool (2024-2034) across the seven major markets?

What are the key factors driving the epidemiological trend of Lennox-Gastaut syndrome?

What will be the growth rate of patients across the seven major markets?

## Lennox-Gastaut Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

What are the current marketed drugs and what are their market performance?

What are the key pipeline drugs and how are they expected to perform in the coming years?

How safe are the current marketed drugs and what are their efficacies?

How safe are the late-stage pipeline drugs and what are their efficacies?

What are the current treatment guidelines for Lennox-Gastaut syndrome drugs across

the seven major markets?

Who are the key companies in the market and what are their market shares?

What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Lennox-Gastaut syndrome market?

What are the key regulatory events related to the Lennox-Gastaut syndrome market?

What is the structure of clinical trial landscape by status related to the Lennox-Gastaut syndrome market?

What is the structure of clinical trial landscape by phase related to the Lennox-Gastaut syndrome market?

What is the structure of clinical trial landscape by route of administration related to the Lennox-Gastaut syndrome market?

## Contents

### **1 PREFACE**

### **2 SCOPE AND METHODOLOGY**

- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
  - 2.3.1 Primary Sources
  - 2.3.2 Secondary Sources
- 2.4 Market Estimation
  - 2.4.1 Bottom-Up Approach
  - 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology

### **3 EXECUTIVE SUMMARY**

### **4 LENNOX-GASTAUT SYNDROME - INTRODUCTION**

- 4.1 Overview
- 4.2 Regulatory Process
- 4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
- 4.4 Market Overview (2018-2023) and Forecast (2024-2034)
- 4.5 Competitive Intelligence

### **5 LENNOX-GASTAUT SYNDROME - DISEASE OVERVIEW**

- 5.1 Introduction
- 5.2 Symptoms and Diagnosis
- 5.3 Pathophysiology
- 5.4 Causes and Risk Factors
- 5.5 Treatment

### **6 PATIENT JOURNEY**

### **7 LENNOX-GASTAUT SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION**

- 7.1 Epidemiology - Key Insights

- 7.2 Epidemiology Scenario - Top 7 Markets
  - 7.2.1 Epidemiology Scenario (2018-2023)
  - 7.2.2 Epidemiology Forecast (2024-2034)
  - 7.2.3 Epidemiology by Age (???2018-2034)
  - 7.2.4 Epidemiology by Gender (???2018-2034)
  - 7.2.5 Diagnosed Cases (???2018-2034)
  - 7.2.6 Patient Pool/Treated Cases (???2018-2034)
- 7.3 Epidemiology Scenario - United States
  - 7.3.1 Epidemiology Scenario (2018-2023)
  - 7.3.2 Epidemiology Forecast (2024-2034)
  - 7.3.3 Epidemiology by Age (???2018-2034)
  - 7.3.4 Epidemiology by Gender (???2018-2034)
  - 7.3.5 Diagnosed Cases (???2018-2034)
  - 7.3.6 Patient Pool/Treated Cases (???2018-2034)
- 7.4 Epidemiology Scenario - Germany
  - 7.4.1 Epidemiology Scenario (2018-2023)
  - 7.4.2 Epidemiology Forecast (2024-2034)
  - 7.4.3 Epidemiology by Age (???2018-2034)
  - 7.4.4 Epidemiology by Gender (???2018-2034)
  - 7.4.5 Diagnosed Cases (???2018-2034)
  - 7.4.6 Patient Pool/Treated Cases (???2018-2034)
- 7.5 Epidemiology Scenario - France
  - 7.5.1 Epidemiology Scenario (2018-2023)
  - 7.5.2 Epidemiology Forecast (2024-2034)
  - 7.5.3 Epidemiology by Age (???2018-2034)
  - 7.5.4 Epidemiology by Gender (???2018-2034)
  - 7.5.5 Diagnosed Cases (???2018-2034)
  - 7.5.6 Patient Pool/Treated Cases (???2018-2034)
- 7.6 Epidemiology Scenario - United Kingdom
  - 7.6.1 Epidemiology Scenario (2018-2023)
  - 7.6.2 Epidemiology Forecast (2024-2034)
  - 7.6.3 Epidemiology by Age (???2018-2034)
  - 7.6.4 Epidemiology by Gender (???2018-2034)
  - 7.6.5 Diagnosed Cases (???2018-2034)
  - 7.6.6 Patient Pool/Treated Cases (???2018-2034)
- 7.7 Epidemiology Scenario - Italy
  - 7.7.1 Epidemiology Scenario (2018-2023)
  - 7.7.2 Epidemiology Forecast (2024-2034)
  - 7.7.3 Epidemiology by Age (???2018-2034)

- 7.7.4 Epidemiology by Gender (???2018-2034)
- 7.7.5 Diagnosed Cases (???2018-2034)
- 7.7.6 Patient Pool/Treated Cases (???2018-2034)
- 7.8 Epidemiology Scenario - Spain
  - 7.8.1 Epidemiology Scenario (2018-2023)
  - 7.8.2 Epidemiology Forecast (2024-2034)
  - 7.8.3 Epidemiology by Age (???2018-2034)
  - 7.8.4 Epidemiology by Gender (???2018-2034)
  - 7.8.5 Diagnosed Cases (???2018-2034)
  - 7.8.6 Patient Pool/Treated Cases (???2018-2034)
- 7.9 Epidemiology Scenario - Japan
  - 7.9.1 Epidemiology Scenario (2018-2023)
  - 7.9.2 Epidemiology Forecast (2024-2034)
  - 7.9.3 Epidemiology by Age (???2018-2034)
  - 7.9.4 Epidemiology by Gender (???2018-2034)
  - 7.9.5 Diagnosed Cases (???2018-2034)
  - 7.9.6 Patient Pool/Treated Cases (???2018-2034)

## **8 LENNOX-GASTAUT SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES**

- 8.1 Guidelines, Management and Treatment
- 8.2 Treatment Algorithm

## **9 LENNOX-GASTAUT SYNDROME - UNMET NEEDS**

## **10 LENNOX-GASTAUT SYNDROME - KEY ENDPOINTS OF TREATMENT**

## **11 LENNOX-GASTAUT SYNDROME - MARKETED PRODUCTS**

- 11.1 List of Lennox-Gastaut Syndrome Marketed Drugs Across the Top 7 Markets
  - 11.1.1 Epidiolex (Cannabidiol) - Greenwich Biosciences
    - 11.1.1.1 Drug Overview
    - 11.1.1.2 Mechanism of Action
    - 11.1.1.3 Regulatory Status
    - 11.1.1.4 Clinical Trial Results
    - 11.1.1.5 Sales Across Major Markets
  - 11.1.2 Fintepla (Fenfluramine) - Zogenix
    - 11.1.2.1 Drug Overview



- 11.1.2.2 Mechanism of Action
- 11.1.2.3 Regulatory Status
- 11.1.2.4 Clinical Trial Results
- 11.1.2.5 Sales Across Major Markets
- 11.1.3 Banzel (Rufinamide) - Eisai
  - 11.1.3.1 Drug Overview
  - 11.1.3.2 Mechanism of Action
  - 11.1.3.3 Regulatory Status
  - 11.1.3.4 Clinical Trial Results
  - 11.1.3.5 Sales Across Major Markets
- 11.1.4 Topamax (Topiramate) - Janssen Pharmaceuticals
  - 11.1.4.1 Drug Overview
  - 11.1.4.2 Mechanism of Action
  - 11.1.4.3 Regulatory Status
  - 11.1.4.4 Clinical Trial Results
  - 11.1.4.5 Sales Across Major Markets
- 11.1.5 Lamictal (Lamotrigine) - GlaxoSmithKline
  - 11.1.5.1 Drug Overview
  - 11.1.5.2 Mechanism of Action
  - 11.1.5.3 Regulatory Status
  - 11.1.5.4 Clinical Trial Results
  - 11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report

## **12 LENNOX-GASTAUT SYNDROME - PIPELINE DRUGS**

- 12.1 List of Lennox-Gastaut Syndrome Pipeline Drugs Across the Top 7 Markets
  - 12.1.1 Clemizole HCl - Epygenix
    - 12.1.1.1 Drug Overview
    - 12.1.1.2 Mechanism of Action
    - 12.1.1.3 Clinical Trial Results
    - 12.1.1.4 Safety and Efficacy
    - 12.1.1.5 Regulatory Status
  - 12.1.2 Soticlestat - Takeda
    - 12.1.2.1 Drug Overview
    - 12.1.2.2 Mechanism of Action
    - 12.1.2.3 Clinical Trial Results
    - 12.1.2.4 Safety and Efficacy

- 12.1.2.5 Regulatory Status
- 12.1.3 Carisbamate - SK Life Science
  - 12.1.3.1 Drug Overview
  - 12.1.3.2 Mechanism of Action
  - 12.1.3.3 Clinical Trial Results
  - 12.1.3.4 Safety and Efficacy
  - 12.1.3.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report

## **13 LENNOX-GASTAUT SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS**

## **14 LENNOX-GASTAUT SYNDROME – CLINICAL TRIAL LANDSCAPE**

- 14.1 Drugs by Status
- 14.2 Drugs by Phase
- 14.3 Drugs by Route of Administration
- 14.4 Key Regulatory Events

## **15 LENNOX-GASTAUT SYNDROME - MARKET SCENARIO**

- 15.1 Market Scenario - Key Insights
- 15.2 Market Scenario - Top 7 Markets
  - 15.2.1 Lennox-Gastaut Syndrome - Market Size
    - 15.2.1.1 Market Size (2018-2023)
    - 15.2.1.2 Market Forecast (2024-2034)
  - 15.2.2 Lennox-Gastaut Syndrome - Market Size by Therapies
    - 15.2.2.1 Market Size by Therapies (2018-2023)
    - 15.2.2.2 Market Forecast by Therapies (2024-2034)
- 15.3 Market Scenario - United States
  - 15.3.1 Lennox-Gastaut Syndrome - Market Size
    - 15.3.1.1 Market Size (2018-2023)
    - 15.3.1.2 Market Forecast (2024-2034)
  - 15.3.2 Lennox-Gastaut Syndrome - Market Size by Therapies
    - 15.3.2.1 Market Size by Therapies (2018-2023)
    - 15.3.2.2 Market Forecast by Therapies (2024-2034)
  - 15.3.3 Lennox-Gastaut Syndrome - Access and Reimbursement Overview
- 15.4 Market Scenario - Germany

- 15.4.1 Lennox-Gastaut Syndrome - Market Size
  - 15.4.1.1 Market Size (2018-2023)
  - 15.4.1.2 Market Forecast (2024-2034)
- 15.4.2 Lennox-Gastaut Syndrome - Market Size by Therapies
  - 15.4.2.1 Market Size by Therapies (2018-2023)
  - 15.4.2.2 Market Forecast by Therapies (2024-2034)
- 15.4.3 Lennox-Gastaut Syndrome - Access and Reimbursement Overview
- 15.5 Market Scenario - France
  - 15.5.1 Lennox-Gastaut Syndrome - Market Size
    - 15.5.1.1 Market Size (2018-2023)
    - 15.5.1.2 Market Forecast (2024-2034)
  - 15.5.2 Lennox-Gastaut Syndrome - Market Size by Therapies
    - 15.5.2.1 Market Size by Therapies (2018-2023)
    - 15.5.2.2 Market Forecast by Therapies (2024-2034)
  - 15.5.3 Lennox-Gastaut Syndrome - Access and Reimbursement Overview
- 15.6 Market Scenario - United Kingdom
  - 15.6.1 Lennox-Gastaut Syndrome - Market Size
    - 15.6.1.1 Market Size (2018-2023)
    - 15.6.1.2 Market Forecast (2024-2034)
  - 15.6.2 Lennox-Gastaut Syndrome - Market Size by Therapies
    - 15.6.2.1 Market Size by Therapies (2018-2023)
    - 15.6.2.2 Market Forecast by Therapies (2024-2034)
  - 15.6.3 Lennox-Gastaut Syndrome - Access and Reimbursement Overview
- 15.7 Market Scenario - Italy
  - 15.7.1 Lennox-Gastaut Syndrome - Market Size
    - 15.7.1.1 Market Size (2018-2023)
    - 15.7.1.2 Market Forecast (2024-2034)
  - 15.7.2 Lennox-Gastaut Syndrome - Market Size by Therapies
    - 15.7.2.1 Market Size by Therapies (2018-2023)
    - 15.7.2.2 Market Forecast by Therapies (2024-2034)
  - 15.7.3 Lennox-Gastaut Syndrome - Access and Reimbursement Overview
- 15.8 Market Scenario - Spain
  - 15.8.1 Lennox-Gastaut Syndrome - Market Size
    - 15.8.1.1 Market Size (2018-2023)
    - 15.8.1.2 Market Forecast (2024-2034)
  - 15.8.2 Lennox-Gastaut Syndrome - Market Size by Therapies
    - 15.8.2.1 Market Size by Therapies (2018-2023)
    - 15.8.2.2 Market Forecast by Therapies (2024-2034)
  - 15.8.3 Lennox-Gastaut Syndrome - Access and Reimbursement Overview

## 15.9 Market Scenario - Japan

### 15.9.1 Lennox-Gastaut Syndrome - Market Size

#### 15.9.1.1 Market Size (2018-2023)

#### 15.9.1.2 Market Forecast (2024-2034)

### 15.9.2 Lennox-Gastaut Syndrome - Market Size by Therapies

#### 15.9.2.1 Market Size by Therapies (2018-2023)

#### 15.9.2.2 Market Forecast by Therapies (2024-2034)

### 15.9.3 Lennox-Gastaut Syndrome - Access and Reimbursement Overview

## **16 LENNOX-GASTAUT SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS**

## **17 LENNOX-GASTAUT SYNDROME MARKET - SWOT ANALYSIS**

### 17.1 Strengths

### 17.2 Weaknesses

### 17.3 Opportunities

### 17.4 Threats

## **18 LENNOX-GASTAUT SYNDROME MARKET – STRATEGIC RECOMMENDATIONS**

## **19 APPENDIX**

## I would like to order

Product name: Lennox-Gastaut Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Product link: <https://marketpublishers.com/r/LCDA42516D72EN.html>

Price: US\$ 6,499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/LCDA42516D72EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

